Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Key Points

Biotech stocks have a reputation for being high risk, high reward.
Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
5 stocks we like better than Denali Therapeutics

Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

→ Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad)

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Denali Therapeutics (DNLI)	3.6116 of 5 stars	$16.60	-1.3%	N/A	-15.37	Buy	$41.22
Ultragenyx Pharmaceutical (RARE)	4.3123 of 5 stars	$43.38	-1.7%	N/A	-5.21	Moderate Buy	$91.55
Sarepta Therapeutics (SRPT)	4.8695 of 5 stars	$116.55	-1.1%	N/A	-19.04	Moderate Buy	$158.38
Pfizer (PFE)	4.9926 of 5 stars	$25.39	-0.1%	6.62%	70.51	Hold	$36.88
Exelixis (EXEL)	4.982 of 5 stars	$22.49	-1.7%	N/A	35.14	Moderate Buy	$26.29
Moderna (MRNA)	3.8685 of 5 stars	$102.00	-1.4%	N/A	-8.22	Hold	$126.49
United Therapeutics (UTHR)	4.368 of 5 stars	$236.93	+0.7%	N/A	11.94	Moderate Buy	$292.67
Biogen (BIIB)	4.9048 of 5 stars	$190.52	-0.9%	N/A	23.87	Moderate Buy	$297.73
Sanofi (SNY)	3.2087 of 5 stars	$45.39	-1.6%	3.04%	19.23	Hold	$55.00
Eli Lilly and Company (LLY)	4.8162 of 5 stars	$745.95	-0.6%	0.70%	128.61	Moderate Buy	$728.05